Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Sarcoma 2Lymphoid 2Other hematologic neoplasm 1NET 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Sarcoma, Endometrial Stromal 2Sarcoma 2Pheochromocytoma 2Ovarian Neoplasms 2Neurofibrosarcoma 2Neoplasm Metastasis 2Malignant mesenchymal tumor 2Liposarcoma 2Leiomyosarcoma 2Kidney Neoplasms 2Histiocytoma, Malignant Fibrous 2Hemangiosarcoma 2Hemangiopericytoma, Malignant 2Head and Neck Neoplasms 2Fibrosarcoma 2Endometrial Neoplasms 2Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1Adrenocortical Carcinoma 1

Interventions

Everolimus 2trifluridine tipiracil drug combination 1surufatinib 1pegfilgrastim 1pasireotide 1gallium Ga 68 dotatate 1fosbretabulin 1entinostat 1dactolisib 1belzutifan 1Temozolomide 1TH 302 1Surveys and Questionnaires 1Sunitinib 1Photochemotherapy 1Nivolumab 1Filgrastim 1Fentanyl 1Dihematoporphyrin Ether 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Filgrastim × Endocrine × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡